文章基本信息

标题：A large scale study of angiotensin II inhibition therapy in an elderly population: the CHANCE study
本地全文：下载
作者：Roland Asmar ; Sophie Nisse-Durgeat
期刊名称：Vascular Health and Risk Management
印刷版ISSN：1176-6344
电子版ISSN：1178-2048
出版年度：2006
卷号：2
期号：3
页码：317-323
出版社：Dove Medical Press Ltd
摘要：This 8-week, multicenter study evaluated the efficacy and safety of candesartan cilexetil (CC, 8–16 mg) in elderly (>65 years) hypertensive patients. Patients (n=3013) received CC 8 mg during 8 weeks which eventually doubled to CC 16 mg at week 4 if blood pressure remained uncontrolled (>140/90 mmHg). At week 8, 65.5% of patients were normalized (BP <140/90 mmHg). Mean changes at week 8 were –25.8, –13.2, and –12.7 mmHg for systolic, diastolic, and pulse pressure, respectively. Age, sex, and diabetic status did not influence the antihypertensive effect of CC. 68% of the patients treated with, but uncontrolled or intolerant of, prior antihypertensive treatment were normalized by CC 8–16 mg. In summary, CC 8– 16 mg once daily was effective and well tolerated in the management of arterial hypertension in elderly subjects.
关键词：candesartan cilexetil; angiotensin II receptor antagonist; hypertension; elderly subject; CHANCE study